BURST CME™: How Does Transfusion Burden Impact Real-World Outcomes in MDS?
BURST CME™: How Does Transfusion Burden Impact Real-World Outcomes in MDS? is organized by Physicians' Education Resource, LLC (PER).
Release Date: March 23, 2023
Expiration Date: March 23, 2024
Description:
Lower-risk myelodysplastic syndromes (LR-MDS) comprise a heterogeneous set of hematologic malignancies characterized by hallmark cytopenias that can lead to a significant transfusion burden. New treatment options and best practices are poised to alter the standard of care for LR-MDS.
This activity focuses on the real-world impact of transfusion burden on the outcomes of patients with LR-MDS, as well as the approaches in development intended to alter the disease course. This written material is supplemented by interviews with expert faculty who provide insight into best practices and emerging treatment approaches for LR-MDS.
Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
Explain how transfusion burden impacts patient- and disease-related outcomes among patients with LR-MDS
Determine clinically unmet gaps related to transfusion burden with standard approaches for LR-MDS management based on evolving trial and real-world evidence
Identify emerging strategies for the treatment of LR-MDS with the potential to address the problem of transfusion burden among patients with MDS.